1 – 10 of 56
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
AlphaML : A clear, legible, explainable, transparent, and elucidative binary classification platform for tabular data
(
- Contribution to journal › Article
- 2023
-
Mark
Understanding the Role of Activation Loop Mutants in Drug Efficacy for FLT3-ITD
(
- Contribution to journal › Article
-
Mark
A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia
(
- Contribution to journal › Article
- 2022
-
Mark
Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance
(
- Contribution to journal › Article
- 2019
-
Mark
FMS-like Tyrosine Kinase 3/FLT3 : From Basic Science to Clinical Implications
(
- Contribution to journal › Article
-
Mark
The role of SRC family kinases in FLT3 signaling
(
- Contribution to journal › Scientific review
-
Mark
The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
(
- Contribution to journal › Letter
-
Mark
Metallopeptidase inhibitor 1 (TIMP-1) promotes receptor tyrosine kinase c-Kit signaling in colorectal cancer
(
- Contribution to journal › Article
- 2018
-
Mark
SRC-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation
(
- Contribution to journal › Article
-
Mark
Bruton’s tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma
(
- Contribution to journal › Article